Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of California
Headquarters: Oakland, CA, United States of America
Website: http://www.universityofcali...
Year Founded: 1868
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Apr 5, 2025
Discovery & Translation
Science Spotlight: A FOXP3 regulator to enhance induced Tregs
BioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and more
BioCentury | Feb 27, 2025
Discovery & Translation
Science Spotlight: Clues from the clinic for neoantigen prioritization
BioCentury’s roundup of translational innovations also includes causal biology for a heart condition, and the biological foundational model Evo 2
BioCentury | Feb 22, 2025
Discovery & Translation
Science Spotlight: Bacterial payload delivery from nose to brain
BioCentury’s roundup of translational innovations also includes targeting MSH3 to slow repeat expansion in Huntington’s; plus AAVs for kidney and T cells
BioCentury | Feb 13, 2025
Emerging Company Profile
Unnatural: Expanding the macrocyclic peptide chemical space
Company applying small molecule optimization techniques to peptides with a robotic synthesis platform
BioCentury | Feb 7, 2025
Discovery & Translation
Science Spotlight: Ranking AAV capsids for liver gene therapy
BioCentury’s roundup of translational innovation also includes high-resolution spatial proteomics, a more diverse microbiome atlas, and more
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Dec 12, 2024
Deals
Nvelop, Chroma merger creates opportunity for targeted epigenome editors
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
BioCentury | Dec 12, 2024
Management Tracks
Two more C-suite hires at Xaira
Plus: Accent’s Copeland to retire and updates from ProQR, Kashiv and Aculeus
BioCentury | Nov 27, 2024
Discovery & Translation
Science Spotlight: Reducing immune rejection of stem cell-derived therapies
BioCentury’s roundup of translational innovation also includes a new target for arrhythmia and four papers with links to newcos
BioCentury | Nov 26, 2024
Politics, Policy & Law
Marty Makary’s turn in the spotlight
Trump’s FDA commissioner pick has complex, controversial history
Items per page:
1 - 10 of 3126